Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Vertex Pharmaceuticals to $385 from $339 and keeps a Buy rating on the shares. With the company having established a FY23 outlook on February 7, the Q1 print "was a nonevent," says the analyst, who thinks consensus might be underestimating VX-548’s commercial outlook. The firm’s higher target follows incorporation of -548 in its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $384 from $342 at Barclays
- Vertex Pharmaceuticals reports Q1 EPS $2.69, consensus $3.00
- Vertex options imply 3.8% move in share price post-earnings
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex announces U.S. FDA approval for expanded use of Trikafta